The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 20, 2018

Filed:

Nov. 24, 2015
Applicant:

International Stem Cell Corporation, Carlsbad, CA (US);

Inventors:

Elena S. Revazova, Santa Monica, CA (US);

Leonid N. Kuzmichev, Moscow, RU;

Nickolay A. Turovets, Carlsbad, CA (US);

Jeffrey D. Janus, San Ramon, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/545 (2015.01); C12N 5/0735 (2010.01); C12N 5/075 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0606 (2013.01); A61K 35/545 (2013.01); C12N 5/0609 (2013.01); C12N 2500/02 (2013.01); C12N 2500/14 (2013.01); C12N 2501/115 (2013.01); C12N 2501/235 (2013.01); C12N 2502/1323 (2013.01);
Abstract

Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.


Find Patent Forward Citations

Loading…